Prevalence of lower urinary tract symptoms in taxi drivers: a cross-sectional web-based survey-Reference-Cited by-同舟云学术

Prevalence of lower urinary tract symptoms in taxi drivers: a cross-sectional web-based survey

Published:2023-12-30 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Li Marzi Vincenzo^ORCID,Musco Stefania,Lombardo Riccardo^ORCID,Cicione Antonio,Gemma Luca,Morselli Simone,Gallo Maria Lucia,Serni Sergio,Campi Riccardo,De Nunzio Cosimo^ORCID,Albisinni Simone,De Cillis Sabrina,Geretto Paolo,Pellizzari Laura,Sampogna Gianluca,Vacca Lorenzo,

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-023-00777-w.pdf

Reference31 articles.

1. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289–97

2. Huang J, Chan CK, Yee S, Deng Y, Bai Y, Chan SC, et al. Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022;26:421–28

3. De Nunzio C, Franco A, Lombardo R. LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations. Prostate Cancer Prostatic Dis. 2021;25:5–6

4. Ornaghi PI, Porreca A, Sandri M, Sciarra A, Falsaperla M, Ludovico GM, et al. Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases. Prostate Cancer Prostatic Dis. 2022;26:730–35

5. Sahakyan Y, Erman A, Bhojani N, Chughtai B, Zorn KC, Sander B, et al. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study. Prostate Cancer Prostatic Dis Nat. 2022;26:113–8.